Advances of lipid-lowering therapy in the elderly
LIU Mei-lin
Abstract：Statins treatment can reduce mortality of atherosclerotic cardiovascular disease (ASCVD) and reduce cardiovascular events.Because of the high prevalence of cardiovascular disease in the elderly and the greater risk of cardiovascular events,some data show an even greater absolute risk reduction in the elderly.Currently, there is a few of clinical evidence for prospective,randomized,controlled,large-scale clinical trials designed for octogenarian and no evidence of high-dose statin therapy to benefit the very elderly.LDL-C is the primary goal of dyslipidemia management in the elderly,and non-HDL-C is a secondary goal.Healthy diet and lifestyle is the basic measure of treatment for dyslipidemia in the elderly,statins are the preferred lipid-lowering drugs.It is suggested that the risk stratification and individual characteristics of patients with cardiovascular disease should be evaluated according to the benefits and harm of lipid-lowering therapy.The lipid-lowering drugs should be selected in order to improve the quality oflife,reduce the cardiovascular events and reduce the mortality.
Keywords：elderlyASCVDdyslipidemiastatinlipid-lowering therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 293-296 )